4,4'-([1,2,5]Thiadiazolo[3,4-c]pyridine-4,7-diyl)dibenzaldehyde

Catalog No. :
ACDPAZ570
CAS No. :
2757730-01-9
Molecular Formula :
C19H11N3O2S
Molecular Weight :
345.38

IUPAC Name:4,4'-([1,2,5]thiadiazolo[3,4-c]pyridine-4,7-diyl)dibenzaldehyde

4,4'-([1,2,5]Thiadiazolo[3,4-c]pyridine-4,7-diyl)dibenzaldehyde structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg95%$111.00Login to see priceIn stockIn stock
250mg95%$223.00Login to see priceIn stockIn stock
1g95%$585.00Login to see priceIn stockIn stock
5g95%$2516.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name4,4'-([1,2,5]Thiadiazolo[3,4-c]pyridine-4,7-diyl)dibenzaldehyde
IUPAC Name4,4'-([1,2,5]thiadiazolo[3,4-c]pyridine-4,7-diyl)dibenzaldehyde
Molecular FormulaC19H11N3O2S
Molecular Weight345.38
SMILESO=CC1=CC=C(C2=NC=C(C3=CC=C(C=C3)C=O)C4=NSN=C24)C=C1
InChI KeySDULRKVMCJLTDI-UHFFFAOYSA-N
Synonym4,4'-([1,2,5]Thiadiazolo[3,4-c]pyridine-4,7-diyl)dibenzaldehyde
CAS No.2757730-01-9
PubChem CID162394007

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACDPAZ570 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACYVBO782 route compound structure diagram
    ACYVBO78287199-17-5 In Stock
  4. Then
  5. ACDPAZ570 route product structure diagram
    ACDPAZ5702757730-01-9 In Stock
Inquiry

2. ACDPAZ570 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACYVBO782 route compound structure diagram
    ACYVBO78287199-17-5 In Stock
  4. Then
  5. ACDPAZ570 route product structure diagram
    ACDPAZ5702757730-01-9 In Stock
Inquiry

Comments (0)